Cannapharmarx - CPMD STOCK NEWS

CannaPharmaRx (OTC PINK: CPMD) has entered into an agreement with a new head grower to enhance their cannabis cultivation capabilities at the Cremona facility, formerly known as the Aurora Mountain facility, which can produce up to 6,000 kg/year. The company expects to complete its first harvest by early Q3 2022, with anticipated annual revenue exceeding $30 million. With EUGMP and GACP certifications, products can be sold in Europe and Israel, marking a significant advancement in CannaPharmaRx's production and distribution strategy.

CannaPharmaRx, Inc. (OTC PINK:CPMD) has announced the hiring of three key personnel to enhance its cannabis production capabilities. Jeremy Metro joins as head grower, bringing extensive cultivation experience, while Jason Buxton serves as quality manager, ensuring product safety and compliance. Rob Osterdal has been appointed head of security, leveraging his management experience at Aurora Cannabis. CEO Nick Colvin stated that these hires aim to expedite product market entry and establish CannaPharmaRx as a leader in the cannabis industry during the current quarter.

CannaPharmaRx (OTC PINK:CPMD) has finalized a 20-year operating lease for the Cremona, Alberta cannabis production facility, previously owned by Aurora Cannabis. This 55,200-square foot facility can produce 6,000 kg/year of cannabis. With plans to obtain EUGMP and GACP certifications, the company aims to enter European and Israeli markets. Expected first harvest and sales are set for Q3 2022, with projected annual revenue surpassing $30 million. CEO Nick Colvin labeled the lease a significant milestone for the company.

CannapharmaRx, Inc. (OTC PINK:CPMD) announced the sale of its Hanover, Ontario facility for $2,000,000 CAD, which spans ten acres and features 48,800 square feet of growing space. The sale was unanimously approved by management to eliminate debt and improve the company's balance sheet. CEO Nick Colvin emphasized that this decision aligns with their strategy to acquire more technologically advanced cannabis production facilities. CannapharmaRx aims to lead in the efficient production of cannabis in Canada through modernization and enhancement of their facilities.

CannaPharmaRx (OTC PINK: CPMD) addressed a press release from an unaffiliated third party that promoted the company without authorization. Management confirmed they did not engage with these groups, highlighting that the promotional statements contained predictions rather than factual information. No significant trading price changes occurred around the promotional activity. The company emphasizes reliance on official SEC filings for accurate information. CannaPharmaRx is developing a 48,500 square foot cannabis grow facility and plans to list on the Canadian Stock Exchange and OTCQB.

CannapharmaRx, Inc. (OTC PINK:CPMD) has signed a formal agreement with K&K Consulting to increase its presence in the Israeli medical cannabis market. The patient count in Israel reached over 60,000 in 2020, but local compliance issues have led to a reliance on imports. This agreement grants CannapharmaRx access to Israeli capital markets, potentially easing financing for its ventures. The company aims to lead in cannabis production by developing state-of-the-art facilities.

CannapharmaRx, Inc. (OTC PINK:CPMD) announced the sale of its Hanover, Ontario facility for $2,000,000 CAD. The facility spans ten acres with 48,800 square feet of growing space. The decision to sell was made by senior management to focus on acquiring a more advanced facility in Cremona, Alberta, which will enhance production capabilities, enabling the company to produce 5,200 kilograms of cannabis annually. The transaction is set to close on June 30, 2021, improving the company's balance sheet and reducing certain liabilities.

CannapharmaRx, Inc. (OTC PINK: CPMD) recently announced a restructuring of its Board of Directors, effective March 12, 2021, with Jim Samuelson and Matt Nicosia resigning to focus on other business obligations. Their departures were not due to disagreements with the company. CEO Nick Colvin expressed gratitude for their contributions as CannapharmaRx prepares for significant asset acquisitions in Saskatchewan and Alberta, expected to close in April 2021. The company aims to enhance its position in high-technology cannabis production and has a 48,500 square foot grow facility under development.

CannapharmaRx, Inc. (OTC PINK:CPMD) announced a strategic partnership with Klonetics Plant Science, Inc. on September 30, 2020. This collaboration will utilize CannapharmaRx's business expertise to support Klonetics' projects in genetic acquisition and cannabis cultivation. CannapharmaRx will also acquire a minority stake in Klonetics, granting them exclusivity to certain intellectual properties, potentially enhancing their market competitiveness. CannapharmaRx is developing a 48,500 square foot cannabis facility and plans to list its shares on the Canadian Stock Exchange.